Thomas Civik - Interim CEO, Director at Pyxis Oncology, Inc.

Issuer-level insider activity

Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Individual
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

No buys or sells have been reported by Thomas Civik since 07 Sep 2025

Reported holdings for Thomas Civik in Pyxis Oncology, Inc.

Form 4 holding Interim CEO, Director

Pyxis Oncology, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
941,087
Estimated value
$36,239
Report date
12 Aug 2026
Price
$0.9800
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Transaction history for Thomas Civik in Pyxis Oncology, Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .